KR20250065723A - 멸균 처리한 헤테로시클리덴아세트아미드 유도체 함유 현탁액 - Google Patents

멸균 처리한 헤테로시클리덴아세트아미드 유도체 함유 현탁액 Download PDF

Info

Publication number
KR20250065723A
KR20250065723A KR1020257013712A KR20257013712A KR20250065723A KR 20250065723 A KR20250065723 A KR 20250065723A KR 1020257013712 A KR1020257013712 A KR 1020257013712A KR 20257013712 A KR20257013712 A KR 20257013712A KR 20250065723 A KR20250065723 A KR 20250065723A
Authority
KR
South Korea
Prior art keywords
aqueous suspension
trifluoromethylchroman
tetrahydronaphthalen
ylidene
acetamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257013712A
Other languages
English (en)
Korean (ko)
Inventor
유키 야마시타
Original Assignee
센주 세이야꾸 가부시키가이샤
모찌다 세이야쿠 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 센주 세이야꾸 가부시키가이샤, 모찌다 세이야쿠 가부시끼가이샤 filed Critical 센주 세이야꾸 가부시키가이샤
Publication of KR20250065723A publication Critical patent/KR20250065723A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020257013712A 2022-09-29 2023-09-28 멸균 처리한 헤테로시클리덴아세트아미드 유도체 함유 현탁액 Pending KR20250065723A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2022-156060 2022-09-29
JP2022156060 2022-09-29
PCT/JP2023/035547 WO2024071348A1 (ja) 2022-09-29 2023-09-28 滅菌処理したヘテロシクリデンアセトアミド誘導体含有懸濁液

Publications (1)

Publication Number Publication Date
KR20250065723A true KR20250065723A (ko) 2025-05-13

Family

ID=90478164

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020257013712A Pending KR20250065723A (ko) 2022-09-29 2023-09-28 멸균 처리한 헤테로시클리덴아세트아미드 유도체 함유 현탁액

Country Status (7)

Country Link
EP (1) EP4595959A1 (https=)
JP (2) JP7589393B2 (https=)
KR (1) KR20250065723A (https=)
CN (1) CN119997937A (https=)
AU (1) AU2023352012A1 (https=)
MX (1) MX2025003326A (https=)
WO (1) WO2024071348A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025206172A1 (ja) * 2024-03-28 2025-10-02 千寿製薬株式会社 電子線滅菌処理したヘテロシクリデンアセトアミド誘導体含有組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021066144A1 (ja) 2019-10-04 2021-04-08 千寿製薬株式会社 ヘテロシクリデンアセトアミド誘導体含有医薬

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ565080A (en) 2005-07-22 2011-03-31 Mochida Pharm Co Ltd Novel heterocyclidene acetamide derivative
JP6230743B1 (ja) 2017-05-31 2017-11-15 持田製薬株式会社 ヘテロシクリデンアセトアミド誘導体の結晶
CN112409191A (zh) 2019-08-23 2021-02-26 持田制药株式会社 光学活性的氨基醇的制备方法
PL4019485T3 (pl) 2019-08-23 2024-10-21 Mochida Pharmaceutical Co., Ltd. Sposób wytwarzania pochodnych heterocyklidenoacetamidu
WO2021039023A1 (ja) 2019-08-23 2021-03-04 持田製薬株式会社 ヘテロシクリデンアセトアミド誘導体の製造方法
JP7663009B2 (ja) 2021-03-31 2025-04-16 ニデックパワートレインシステムズ株式会社 回転電機、およびポンプ

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021066144A1 (ja) 2019-10-04 2021-04-08 千寿製薬株式会社 ヘテロシクリデンアセトアミド誘導体含有医薬

Also Published As

Publication number Publication date
MX2025003326A (es) 2025-05-02
AU2023352012A1 (en) 2025-04-03
JPWO2024071348A1 (https=) 2024-04-04
JP7589393B2 (ja) 2024-11-25
JP2025024083A (ja) 2025-02-19
CN119997937A (zh) 2025-05-13
WO2024071348A1 (ja) 2024-04-04
EP4595959A1 (en) 2025-08-06

Similar Documents

Publication Publication Date Title
MX2011005217A (es) Formulaciones que comprenden ceftiofur y cetoprofeno o ceftiofur y alcohol bencilico.
US12527740B2 (en) Suspension containing heterocyclidene acetamide derivative
NO325475B1 (no) Farmasoytisk preparat som omfatter ceftiofurhydroklorid, en biokompatibel olje og vann.
US9511022B2 (en) Suspension and cake composition containing carbostyryl derivative and silicone oil and/or silicone oil derivative
KR20250065723A (ko) 멸균 처리한 헤테로시클리덴아세트아미드 유도체 함유 현탁액
EP2571488B1 (en) Pharmaceutical composition of ibuprofen for injection
CN107349181B (zh) 含有瑞巴派特和聚维酮的眼科水悬浮液及其制备方法
CN113952298B (zh) 硫酸头孢喹肟纳米混悬液及其制备方法
KR102912349B1 (ko) 눈의 상황을 치료하기 위한 제제
EA009843B1 (ru) Содержащая циклесонид стерильная водная суспензия
US10463674B2 (en) Process for manufacturing sterile ophthalmic pharmaceutical suspensions
JP7589394B2 (ja) ヘテロシクリデンアセトアミド誘導体を含む配合剤
CA3268119A1 (en) Sterilized heterocyclidene-acetamide-derivative-containing suspension
JP2020527543A (ja) デゾシン類似体エステルを含む徐放懸濁液およびその製造方法
WO2025206172A1 (ja) 電子線滅菌処理したヘテロシクリデンアセトアミド誘導体含有組成物
Kumar et al. Parenteral Suspensions: Stability Enhancing Liquid Dosage Forms
WO2021199076A1 (en) Injectable aripiprazole formulation
BRPI0904401A2 (pt) formulação para distribuição oral

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20250424

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application